Organization

Centre Hospitalier Henri Duffaut

2 clinical trials

3 abstracts

Abstract
Real-world effectiveness and safety of amivantamab for exon 20 EGFR-mutant non-small cell lung cancer (NSCLC) in French early access program: Amexon 20 GFPC.
Org: Hospices Civils of Lyon, Hospital Morvan, Hospital Albert Calmette, CHU Saint-Denis La Réunion, Saint-Denis,
Abstract
Nivolumab (Nivo) plus ipilimumab (Ipi) 6-month treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): 3-year results of the IFCT-1701 DICIPLE phase 3 trial.
Org: Université Paris Cité, Thoracic Oncology Department & CIC Inserm 1425, Hôpital Bichat Claude Bernard, AP-HP.Nord, Hôpital Bichat Claude Bernard, AP-HP.Nord, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,